|
1
|
Kochanowsky JA and Koshy AA: Toxoplasma
gondii. Curr Biol. 28:R770–R771. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Coutermarsh-Ott S: Toxoplasma
gondii as a model of in vivo host-parasite interactions.
Methods Mol Biol. 1960:237–247. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lima TS and Lodoen MB: Mechanisms of human
innate immune evasion by Toxoplasma gondii. Front Cell
Infect Microbiol. 9:1032019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Menard KL, Haskins BE and Denkers EY:
Impact of Toxoplasma gondii infection on host non-coding RNA
responses. Front Cell Infect Microbiol. 9:1322019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Medina L, Castillo C, Liempi A,
Guerrero-Muñoz J, Rojas-Pirela M, Maya JD, Prieto H and Kemmerling
U: Trypanosoma cruzi and Toxoplasma gondii induce a
differential MicroRNA profile in human placental explants. Front
Immunol. 11:5952502020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hou Z, Liu D, Su S, Wang L, Zhao Z, Ma Y,
Li Q, Jia C, Xu J, Zhou Y and Tao J: Comparison of splenocyte
microRNA expression profiles of pigs during acute and chronic
toxoplasmosis. BMC Genomics. 20:972019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li SY, Yang J, Wang LY, Du F, Zhao JL and
Fang R: Expression profile of microRNAs in porcine alveolar
macrophages after Toxoplasma gondii infection. Parasit
Vectors. 12:652019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hu RS, He JJ, Elsheikha HM, Zhang FK, Zou
Y, Zhao GH, Cong W and Zhu XQ: Differential brain MicroRNA
expression profiles after acute and chronic infection of mice with
Toxoplasma gondii oocysts. Front Microbiol. 9:23162018.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sanders KL, Fox BA and Bzik DJ: Attenuated
Toxoplasma gondii therapy of disseminated pancreatic cancer
generates long-lasting immunity to pancreatic cancer.
Oncoimmunology. 5:e11044472015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sanders KL, Fox BA and Bzik DJ: Attenuated
Toxoplasma gondii stimulates immunity to pancreatic cancer
by manipulation of myeloid cell populations. Cancer Immunol Res.
3:891–901. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li Y, Poppoe F, Chen J, Yu L, Deng F, Luo
Q, Xu Y, Cai Y and Shen J: Macrophages polarized by expression of
ToxoGRA15II inhibit growth of hepatic carcinoma. Front
Immunol. 8:1372017.PubMed/NCBI
|
|
12
|
Pyo KH, Lee YW, Lim SM and Shin EH: Immune
adjuvant effect of a Toxoplasma gondii profilin-like protein
in autologous whole-tumor-cell vaccination in mice. Oncotarget.
7:74107–74119. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fox BA, Sanders KL, Rommereim LM, Guevara
RB and Bzik DJ: Secretion of rhoptry and dense granule effector
proteins by nonreplicating Toxoplasma gondii uracil
auxotrophs controls the development of antitumor immunity. PLoS
Genet. 12:e10061892016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu G, Zhou J, Zhao YH, Li QL, Gao YY and
Wang L: Transcriptome sequencing investigated the tumor-related
factors changes after T. gondii infection. Front Microbiol.
10:1812019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang T, Pan H, Wang J, Yang W, Cheng T and
Zhang Q: Identification and profiling of novel and conserved
microRNAs during the flower opening process in Prunus mume via deep
sequencing. Mol Genet Genomics. 289:169–183. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen Y and Wang X: miRDB: An online
database for prediction of functional microRNA targets. Nucleic
Acids Res. 48:D127–D131. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pjevac P, Hausmann B, Schwarz J, Kohl G,
Herbold CW, Loy A and Berry D: An economical and flexible dual
barcoding, two-step PCR approach for highly multiplexed amplicon
sequencing. Front Microbiol. 12:6697762021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li DL, Zou WH, Deng SQ and Peng HJ:
Analysis of the differential exosomal miRNAs of DC2.4 dendritic
cells induced by Toxoplasma gondii infection. Int J Mol Sci.
20:55062019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Acar İE, Saçar Demirci MD, Groß U and
Allmer J: The expressed MicroRNA-mRNA interactions of Toxoplasma
gondii. Front Microbiol. 8:26302018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou CX, Ai K, Huang CQ, Guo JJ, Cong H,
He SY and Zhu XQ: miRNA and circRNA expression patterns in mouse
brain during toxoplasmosis development. BMC Genomics. 21:462020.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hatai H, Lepelley A, Zeng W, Hayden MS and
Ghosh S: Toll-like receptor 11 (TLR11) interacts with flagellin and
profilin through disparate mechanisms. PLoS One. 11:e01489872016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang Y, Jiang WL, Yang JY, Huang J, Kang
G, Hu HB and Xie S: Downregulation of lysyl oxidase-like 4 LOXL4 by
miR-135a-5p promotes lung cancer progression in vitro and in vivo.
J Cell Physiol. 234:18679–18687. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zheng Y, Zheng B, Meng X, Yan Y, He J and
Liu Y: LncRNA DANCR promotes the proliferation, migration, and
invasion of tongue squamous cell carcinoma cells through
miR-135a-5p/KLF8 axis. Cancer Cell Int. 19:3022019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wei X, Yang X, Wang B, Yang Y, Fang Z, Yi
C, Shi L and Song D: LncRNA MBNL1-AS1 represses cell proliferation
and enhances cell apoptosis via targeting miR-135a-5p/PHLPP2/FOXO1
axis in bladder cancer. Cancer Med. 9:724–736. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang Y, Xia F, Zhang F, Cui Y, Wang Q,
Liu H and Wu Y: miR-135b-5p enhances doxorubicin-sensitivity of
breast cancer cells through targeting anterior gradient 2. J Exp
Clin Cancer Res. 38:262019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu B, Zhang J and Yang D: miR-96-5p
promotes the proliferation and migration of ovarian cancer cells by
suppressing caveolae1. J Ovarian Res. 12:572019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Guo LM, Ding GF, Xu WC, Ge H, Jiang Y,
Chen XJ and Lu YF: MiR-135a-5p represses proliferation of HNSCC by
targeting HOXA10. Cancer Biol Ther. 19:973–983. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang X, Qiu J, Kang H, Wang Y and Qian J:
miR-125a-5p suppresses colorectal cancer progression by targeting
VEGFA. Cancer Manag Res. 10:5839–5853. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jing L, Bo W, Yourong F, Tian W, Shixuan W
and Mingfu W: Sema4C mediates EMT inducing chemotherapeutic
resistance of miR-31-3p in cervical cancer cells. Sci Rep.
9:177272019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Furth N, Pateras IS, Rotkopf R, Vlachou V,
Rivkin I, Schmitt I, Bakaev D, Gershoni A, Ainbinder E, Leshkowitz
D, et al: LATS1 and LATS2 suppress breast cancer progression by
maintaining cell identity and metabolic state. Life Sci Alliance.
1:e2018001712018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li J, Chen X, Ding X, Cheng Y, Zhao B, Lai
ZC, Al Hezaimi K, Hakem R, Guan KL and Wang CY: LATS2 suppresses
oncogenic Wnt signaling by disrupting β-catenin/BCL9 interaction.
Cell Rep. 31:1077922020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wu J, Zhao Z, Zhang H, Kong F, Jiang H,
Huang K and Zheng H: LATS1 inhibits metastasis and
epithelial-mesenchymal transition in head and neck squamous cell
carcinoma. Int J Clin Exp Pathol. 11:2053–2063. 2018.PubMed/NCBI
|
